Essential Tremor Clinical Trial
Official title:
Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study
Verified date | January 2014 |
Source | Taro Pharmaceuticals USA |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
This study will evaluate the safety and efficacy of T2000 when used to treat patients with
moderate to severe essential tremor over a 20 week period.
Essential tremor (ET) is a common form of involuntary shaking not related to Parkinson's
disease. The medications that are currently used to treat ET work in a small proportion of
patients and provide only partial improvement in symptoms. Use of these current medications
is also limited by side-effects in many patients.
T2000 is a medication currently under development for the treatment of essential tremor.
Although T2000 is a new medication, it belongs to a class of medications that has been used
for many years for the treatment of a variety of medical conditions. In previous studies,
T2000 appeared to be effective in controlling symptoms of ET and some patients with severe
ET had major improvements in tremor. T2000 was well tolerated for periods up to 20 days and
the minimal side-effects seen were those that would be expected for medications in this
class.
The current study will evaluate the safety and efficacy of T2000 in patients with moderate
to severe essential tremor. Patients will receive doses of T2000 beginning at 600 mg a day,
followed by 800 mg a day and up to 1000 mg a day. The total duration of treatment will be 20
weeks. Patient's tremor and neurological examination will be monitored throughout the study.
The response to T2000 will be determined by comparing the severity of tremor while patients
are receiving T2000 compared to the tremor observed without active medication.
Status | Terminated |
Enrollment | 10 |
Est. completion date | December 2007 |
Est. primary completion date | July 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Confirmed essential tremor by NIH criteria - Significant functional activity limitation due to ET - Patients who have failed, are inadequately treated or cannot tolerate alternative treatments for ET as well as treatment naïve patients who have considered but declined alternative treatment Exclusion Criteria: - Patients adequately controlled without side effects on a current ET treatment - Pregnant patients or patients who may become pregnant during the study - Patients with other medical conditions that may cause tremor, such as Parkinson's disease or active hyperthyroidism - Patients taking medications that might produce tremor or interfere with the evaluation of tremor such as CNS-stimulants or beta-blockers - Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders - Patients with seizure disorders - Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin - Patient with significant general medical or clinical laboratory abnormalities |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Investigator Site | London | Ontario |
Canada | Investigator Site | Ottawa | Ontario |
Canada | Investigator Site | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Taro Pharmaceuticals USA |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of treatment on tremor will be measured by a tremor scale as well as by assessment of functional activity with specific tasks. Patients receiving active treatment will be compared to placebo at 2 months of treatment. | Up to 6 months | No | |
Primary | Response at various dosages will be compared to baseline for all patients. | Up to 6 months | No | |
Secondary | Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication. | Up to 6 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05381688 -
VIM DBS Respiratory Modulation: N-of-1 Trial
|
||
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Completed |
NCT02277106 -
Evaluate SAGE-547 in Participants With Essential Tremor
|
Phase 2 | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Terminated |
NCT02678429 -
Atlas Predicted DBS Settings in Essential Tremor
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02523807 -
Tremor Monitoring Device
|
N/A | |
Active, not recruiting |
NCT02255929 -
Gamma Knife Radiosurgery for Treatment of Essential Tremor
|
N/A | |
Completed |
NCT01223144 -
Decision-making and Emotion Recognition in Essential Tremor
|
N/A | |
Completed |
NCT00906412 -
Ventrointermediate Nucleus (VIM DBS) and Working Memory
|
N/A | |
Recruiting |
NCT05214222 -
Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03051178 -
Wearable Sensor for Responsive DBS for ET
|
N/A | |
Recruiting |
NCT03795935 -
Relief From Side Effects: Clinical Use of Electrodes With Direction
|
N/A | |
Not yet recruiting |
NCT06036368 -
Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor
|
N/A | |
Recruiting |
NCT05897775 -
Coordinated Reset Deep Brain Stimulation for Essential Tremor
|
Phase 1 | |
Recruiting |
NCT05968976 -
Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET
|
N/A | |
Completed |
NCT06314139 -
Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study.
|
N/A | |
Recruiting |
NCT04501133 -
Sensory-specific Peripheral Stimulation for Tremor Management
|
N/A | |
Active, not recruiting |
NCT03560622 -
Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy
|
N/A | |
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A |